Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23701411 | 0.91 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTGFERHTTGAA | |
| SCHEMBL23701410 | 0.91 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTGFERHTTGAA | |
| SCHEMBL27400036 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTGFERPOLBRAB9A | |
| SCHEMBL23701465 | 0.80 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTGFERPOLBRAB9A | |
| SCHEMBL23701466 | 0.80 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTGFERPOLBRAB9A | |
| SCHEMBL23701467 | 0.77 | MAPT (0.44) | SMN1; SMN2MAPTGFERPOLBRAB9A | |
| SCHEMBL23701415 | 0.77 | DRD2 (0.37) | GAAPOLBALDH1A1KDM4E | |
| SCHEMBL23701381 | 0.72 | MAPT (0.43) | SMN1; SMN2MAPTGFERPOLBRAB9A | |
| SCHEMBL29178278 | 0.72 | SMN1; SMN2 (0.75) | SMN1; SMN2MAPTGFERHTTALDH1A1 | |
| SCHEMBL15225851 | 0.71 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTGFERHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | SMN1; SMN2 3383/4885MAPT 4829/4885GFER 783/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | SMN1; SMN2 3383/4885MAPT 4829/4885GFER 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.